Retatrutide

What it helps

Body fat, liver fat, blood sugar and insulin, appetite, and energy use and lean tissue.

Sources

Read the original sources

Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. (Coskun · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
Retatrutide for metabolic dysfunction-associated steatotic liver disease, Sanyal 2024, Nature Medicine (Abstract · checked 2026-10-13)
Shared mechanistic pathways of glucagon signalling in obesity and fatty liver, Neff 2025, Diabetes Obes Metab (Abstract · checked 2026-10-13)
Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)
Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)